Nanotechnology as a Platform for Thermal Therapy of Prostate Cancer

Wei Wang Guihai Chen

doi:10.4172/2155-9929.1000e117

Abstract

Over the past several years, there has been increasing research and clinical interest in using nanotechnology for cancer therapy. Nanoparticle provides tremendous potential for future medical therapy. Besides targeting cancer cells, delivering and releasing drugs in a regulated manner, the specificity of nanoparticles is what makes thermal therapy as attractive as a cancer therapy. In this mini review, we discuss some of the recent advances of nanotechnology for thermal therapy of prostate cancer.

Highlights

Over the past several years, there has been increasing research and clinical interest in using nanotechnology for cancer therapy
Prostate cancer is the second leading cause of cancer death in men, exceeded only by lung cancer. It accounts for 28% of all male cancers and 10% of male cancer-related deaths The PSA test has been used for initial diagnosis of disease, and monitored for recurrence after initial therapy and for prognosis of outcomes
Chemotherapy is a preferred modality in the treatment of prostate cancer, [5] for example; docetaxel and mitoxantrone are considered first-line chemotherapeutic options in patients with hormone-refractory prostate cancer (HRPC) [6]

Summary

Introduction

Over the past several years, there has been increasing research and clinical interest in using nanotechnology for cancer therapy. Anti-PSMA mAbs that bind the extracellular PSMA domain were used in targeting cells for prostate cancer therapy and imaging by several research groups [10,11,12]. Many groups developed aptamers conjugated with nanoparticles for prostate cancer therapy and molecular imaging. Reported the use of A10 PSMA Apt conjugation with PLGA for targeted delivery of cisplatin to prostate cancer cells.

Results

Conclusion